RCS - Physiomics PLC - Physiomics Awarded New Contract

PhysiomicsAnnouncement

12/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260212:nRSL6705Sa&default-theme=true

RNS Number : 6705S  Physiomics PLC  12 February 2026

12 February 2026

 

Physiomics plc

("Physiomics" or the "Company")

 

Physiomics Awarded New Contract

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce a contract award with
a new biopharmaceutical client headquartered in South Korea.

 

This new project is with a South Korean clinical stage biopharmaceutical
company focused on the development of next-generation antibody drug conjugate
(ADC) and Immuno-oncology therapeutic for the treatment of cancer. Under the
terms of the contract, Physiomics will use PK/PD modelling and simulation
techniques to support dosing decisions for one of the client's clinical stage
assets. The project, valued at up to £66,600, will commence immediately with
completion anticipated within the next two months.

 

Dr Peter Sargent, CEO of Physiomics, commented:

"We are thrilled to have been selected to partner with this new South Korean
client on their important clinical stage programme. This engagement
underscores Physiomics' continued commitment to deliver robust quantitative
insights that de-risk development strategies and enhance decision making,
whilst reflecting the Company's efforts to reach new clients in markets
further afield. We look forward to applying our expertise to support this
client in achieving their development goals."

 

For more information about Physiomics and its services, please visit
www.physiomics.co.uk (http://www.physiomics.co.uk) .

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 140 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK. 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAVFLFFQLLXBBL



            Copyright 2019 Regulatory News Service, all rights reserved